Advertisement

Virchows Archiv

, Volume 472, Issue 1, pp 55–66 | Cite as

Autoimmune enteropathies

  • Sarah E. Umetsu
  • Ian Brown
  • Cord Langner
  • Gregory Y. Lauwers
Invited Annual Review Issue

Abstract

Autoimmune enteropathy (AIE) is a rare condition characterized by intractable diarrhea and immune-mediated injury of the intestinal mucosa. As the clinical and histopathologic manifestations of this disease are highly variable, its diagnosis is challenging for both clinicians and pathologists. In fact, the term autoimmune enteropathies is likely more appropriate since the clinicopathologic manifestations are observed in association with a heterogeneous group of disorders. The pathophysiology of AIE has not been fully elucidated. It appears to result from dysregulation of intestinal immunity and particularly in children, often presents in association with immunodeficiency. The overarching histopathologic changes seen in AIE include mucosal inflammation and epithelial injury, although this can manifest in the form of different patterns. Recognition of the clinical settings and of the various histologic patterns can aid the pathologist in establishing the correct diagnosis.

Keywords

Autoimmune disease Immunodeficiency Drug induced Inherited disease Enteritis Colitis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Unsworth DJ, Walker-Smith JA (1985) Autoimmunity in diarrhoeal disease. J Pediatr Gastroenterol Nutr 4(3):375–380CrossRefPubMedGoogle Scholar
  2. 2.
    Akram S, Murray JA, Pardi DS, Alexander GL, Schaffner JA, Russo PA, Abraham SC (2007) Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 5(11):1282–1290; quiz 1245.  https://doi.org/10.1016/j.cgh.2007.05.013 CrossRefGoogle Scholar
  3. 3.
    Catassi C, Fabiani E, Spagnuolo MI, Barera G, Guarino A (1999) Severe and protracted diarrhea: results of the 3-year SIGEP multicenter survey. Working Group of the Italian Society of Pediatric Gastroenterology and Hepatology (SIGEP). J Pediatr Gastroenterol Nutr 29(1):63–68CrossRefPubMedGoogle Scholar
  4. 4.
    Goulet OJ, Brousse N, Canioni D, Walker-Smith JA, Schmitz J, Phillips AD (1998) Syndrome of intractable diarrhoea with persistent villous atrophy in early childhood: a clinicopathological survey of 47 cases. J Pediatr Gastroenterol Nutr 26(2):151–161CrossRefPubMedGoogle Scholar
  5. 5.
    Patey-Mariaud de Serre N, Canioni D, Ganousse S, Rieux-Laucat F, Goulet O, Ruemmele F, Brousse N (2009) Digestive histopathological presentation of IPEX syndrome. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22(1):95–102.  https://doi.org/10.1038/modpathol.2008.161 CrossRefGoogle Scholar
  6. 6.
    Singhi AD, Goyal A, Davison JM, Regueiro MD, Roche RL, Ranganathan S (2014) Pediatric autoimmune enteropathy: an entity frequently associated with immunodeficiency disorders. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 27(4):543–553.  https://doi.org/10.1038/modpathol.2013.150 CrossRefGoogle Scholar
  7. 7.
    Bacchetta R, Barzaghi F, Roncarolo MG (2016) From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci.  https://doi.org/10.1111/nyas.13011
  8. 8.
    Bennett CL, Ochs HD (2001) IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 13(6):533–538CrossRefPubMedGoogle Scholar
  9. 9.
    Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, HC S, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623–1627.  https://doi.org/10.1126/science.1255904 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schaffer AA, Gruning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LS, Sansom DM, Grimbacher B (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20(12):1410–1416.  https://doi.org/10.1038/nm.3746 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, Lyons JJ, Engelhardt KR, Zhang Y, Topcagic N, Roberson ED, Matthews H, Verbsky JW, Dasu T, Vargas-Hernandez A, Varghese N, McClain KL, Karam LB, Nahmod K, Makedonas G, Mace EM, Sorte HS, Perminow G, Rao VK, O’Connell MP, Price S, Su HC, Butrick M, McElwee J, Hughes JD, Willet J, Swan D, Xu Y, Santibanez-Koref M, Slowik V, Dinwiddie DL, Ciaccio CE, Saunders CJ, Septer S, Kingsmore SF, White AJ, Cant AJ, Hambleton S, Cooper MA (2015) Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125(4):591–599.  https://doi.org/10.1182/blood-2014-09-602763 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, Noel RJ, Verbsky JW, Freeman AF, Janssen E, Bonilla FA, Pechacek J, Chandrasekaran P, Browne SK, Agharahimi A, Gharib AM, Mannurita SC, Yim JJ, Gambineri E, Torgerson T, Tran DQ, Milner JD, Holland SM (2013) Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131(6):1611–1623.  https://doi.org/10.1016/j.jaci.2012.11.054 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, Rider NL, Chikwava KR, Cummings OW, Morton DH, Puffenberger EG (2010) Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am J Hum Genet 86(3):447–453.  https://doi.org/10.1016/j.ajhg.2010.01.028 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Verbsky JW, Chatila TA (2013) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr 25(6):708–714.  https://doi.org/10.1097/MOP.0000000000000029 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Walter JE, Farmer JR, Foldvari Z, Torgerson TR, Cooper MA (2016) Mechanism-based strategies for the management of autoimmunity and immune dysregulation in primary immunodeficiencies. J Allergy Clin Immunol Pract 4(6):1089–1100.  https://doi.org/10.1016/j.jaip.2016.08.004 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kisand K, Peterson P (2015) Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol 35(5):463–478.  https://doi.org/10.1007/s10875-015-0176-y CrossRefPubMedGoogle Scholar
  17. 17.
    Agarwal S, Cunningham-Rundles C (2009) Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 9(5):347–352CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Genre J, Errante PR, Kokron CM, Toledo-Barros M, Camara NO, Rizzo LV (2009) Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with common variable immunodeficiency: a link to autoimmunity? Clin Immunol 132(2):215–221.  https://doi.org/10.1016/j.clim.2009.03.519 CrossRefPubMedGoogle Scholar
  19. 19.
    Leon F, Olivencia P, Rodriguez-Pena R, Sanchez L, Redondo C, Alvarez I, Moreira V, Roy G (2004) Clinical and immunological features of adult-onset generalized autoimmune gut disorder. Am J Gastroenterol 99(8):1563–1571.  https://doi.org/10.1111/j.1572-0241.2004.40039.x CrossRefPubMedGoogle Scholar
  20. 20.
    Corazza GR, Biagi F, Volta U, Andreani ML, De Franceschi L, Gasbarrini G (1997) Autoimmune enteropathy and villous atrophy in adults. Lancet 350(9071):106–109.  https://doi.org/10.1016/S0140-6736(97)01042-8 CrossRefPubMedGoogle Scholar
  21. 21.
    Geyer M, Fairchild J, Moore D, Moore L, Henning P, Tham E (2014) Recalcitrant hypocalcaemia in autoimmune enteropathy. Pediatrics 134(6):e1720–e1726.  https://doi.org/10.1542/peds.2013-3308 CrossRefPubMedGoogle Scholar
  22. 22.
    Volta U, De Angelis GL, Granito A, Petrolini N, Fiorini E, Guidi M, Muratori P, Bianchi FB (2006) Autoimmune enteropathy and rheumatoid arthritis: a new association in the field of autoimmunity. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 38(12):926–929.  https://doi.org/10.1016/j.dld.2006.02.003 CrossRefGoogle Scholar
  23. 23.
    Mais DD, Mulhall BP, Adolphson KR, Yamamoto K (1999) Thymoma-associated autoimmune enteropathy. A report of two cases. Am J Clin Pathol 112(6):810–815CrossRefPubMedGoogle Scholar
  24. 24.
    Volta U, Mumolo MG, Caio G, Boschetti E, Latorre R, Giancola F, Paterini P, De Giorgio R (2016) Autoimmune enteropathy: not all flat mucosa mean coeliac disease. Gastroenterology and hepatology from bed to bench 9(2):140–145PubMedPubMedCentralGoogle Scholar
  25. 25.
    Elwing JE, Clouse RE (2005) Adult-onset autoimmune enteropathy in the setting of thymoma successfully treated with infliximab. Dig Dis Sci 50(5):928–932CrossRefPubMedGoogle Scholar
  26. 26.
    Masia R, Peyton S, Lauwers GY, Brown I (2014) Gastrointestinal biopsy findings of autoimmune enteropathy: a review of 25 cases. Am J Surg Pathol 38(10):1319–1329.  https://doi.org/10.1097/PAS.0000000000000317 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Montalto M, D’Onofrio F, Santoro L, Gallo A, Gasbarrini A, Gasbarrini G (2009) Autoimmune enteropathy in children and adults. Scand J Gastroenterol 44(9):1029–1036.  https://doi.org/10.1080/00365520902783691 CrossRefPubMedGoogle Scholar
  28. 28.
    Wurm P, Spindelboeck W, Krause R, Plank J, Fuchs G, Bashir M, Petritsch W, Halwachs B, Langner C, Hogenauer C, Gorkiewicz G (2017) Antibiotic-associated apoptotic enterocolitis in the absence of a defined pathogen: the role of intestinal microbiota depletion. Crit Care Med 45(6):e600–e606.  https://doi.org/10.1097/CCM.0000000000002310 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Abdel-Rahman O, ElHalawani H, Fouad M (2015) Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 7(11):1213–1227.  https://doi.org/10.2217/imt.15.87 CrossRefPubMedGoogle Scholar
  30. 30.
    Mirakian R, Hill S, Richardson A, Milla PJ, Walker-Smith JA, Bottazzo GF (1988) HLA product expression and lymphocyte subpopulations in jejunum biopsies of children with idiopathic protracted diarrhoea and enterocyte autoantibodies. J Autoimmun 1(3):263–277CrossRefPubMedGoogle Scholar
  31. 31.
    Dahan S, Roth-Walter F, Arnaboldi P, Agarwal S, Mayer L (2007) Epithelia: lymphocyte interactions in the gut. Immunol Rev 215:243–253.  https://doi.org/10.1111/j.1600-065X.2006.00484.x CrossRefPubMedGoogle Scholar
  32. 32.
    Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, Freeman GJ, Turley SJ (2009) Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol 182(4):2102–2112.  https://doi.org/10.4049/jimmunol.0802769 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100(14):8372–8377.  https://doi.org/10.1073/pnas.1533209100 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY (2008) Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 32(8):1130–1137.  https://doi.org/10.1097/PAS.0b013e31817150e3 CrossRefPubMedGoogle Scholar
  35. 35.
    Kambayashi T, Laufer TM (2014) Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat Rev Immunol 14(11):719–730.  https://doi.org/10.1038/nri3754 CrossRefPubMedGoogle Scholar
  36. 36.
    Fiocchi C, Roche JK, Michener WM (1989) High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann Intern Med 110(10):786–794CrossRefPubMedGoogle Scholar
  37. 37.
    Martin-Villa JM, Camblor S, Costa R, Arnaiz-Villena A (1993) Gut epithelial cell autoantibodies in AIDS pathogenesis. Lancet 342(8867):380CrossRefPubMedGoogle Scholar
  38. 38.
    Skogh T, Heuman R, Tagesson C (1982) Anti-brush border antibodies (ABBA) in Crohn’s disease. J Clin Lab Immunol 9(3):147–150PubMedGoogle Scholar
  39. 39.
    Biagi F, Bianchi PI, Trotta L, Corazza GR (2009) Anti-goblet cell antibodies for the diagnosis of autoimmune enteropathy? Am J Gastroenterol 104(12):3112.  https://doi.org/10.1038/ajg.2009.511 CrossRefPubMedGoogle Scholar
  40. 40.
    Walker-Smith JA, Unsworth DJ, Hutchins P, Phillips AD, Holborow EJ (1982) Autoantibodies against gut epithelium in child with small-intestinal enteropathy. Lancet 1(8271):566–567CrossRefPubMedGoogle Scholar
  41. 41.
    Moran CJ, Kolman OK, Russell GJ, Brown IS, Mino-Kenudson M (2012) Neutrophilic infiltration in gluten-sensitive enteropathy is neither uncommon nor insignificant: assessment of duodenal biopsies from 267 pediatric and adult patients. Am J Surg Pathol 36(9):1339–1345.  https://doi.org/10.1097/PAS.0b013e318254f413 CrossRefPubMedGoogle Scholar
  42. 42.
    Tegtmeyer D, Seidl M, Gerner P, Baumann U, Klemann C (2017) IBD due to PID: inflammatory bowel disease caused by primary immunodeficiencies-clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.  https://doi.org/10.1111/pai.12734
  43. 43.
    Fontaine JL, Navarro J (1975) Small intestinal biopsy in cows milk protein allergy in infancy. Arch Dis Child 50(5):357–362CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Maluenda C, Phillips AD, Briddon A, Walker-Smith JA (1984) Quantitative analysis of small intestinal mucosa in cow’s milk-sensitive enteropathy. J Pediatr Gastroenterol Nutr 3(3):349–356CrossRefPubMedGoogle Scholar
  45. 45.
    Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C (2017) PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis. Histopathology 70(4):558–567.  https://doi.org/10.1111/his.13118 CrossRefPubMedGoogle Scholar
  46. 46.
    Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec J-Y, Robert C, Carbonnel F, Chaput N (2017) Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathologic entities. J Crohn’s Colitis 11.  https://doi.org/10.1093/ecco-jcc/jjx081
  47. 47.
    Bamias G, Delladetsima I, Perdiki M, Siakavellas SI, Goukos D, Papatheodoridis GV, Daikos GL, Gogas H (2017) Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy. Cancer Investig:1–13.  https://doi.org/10.1080/07357907.2017.1324032
  48. 48.
    Collins M, Michot JM, Danlos FX, Champiat S, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Voisin AL, Soria JC, Marabelle A, Robert C, Carbonnel F (2017) P315 gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. Journal of Crohn’s and Colitis 11 (suppl_1):S237-S237. doi: https://doi.org/10.1093/ecco-jcc/jjx002.440
  49. 49.
    Weidner AS, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, Jessurun J, Yantiss RK (2015) Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol 39(12):1661–1667.  https://doi.org/10.1097/PAS.0000000000000522 CrossRefPubMedGoogle Scholar
  50. 50.
    Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39(12):1653–1660.  https://doi.org/10.1097/PAS.0000000000000525 CrossRefPubMedGoogle Scholar
  51. 51.
    Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, TT W, Murray JA (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87(8):732–738.  https://doi.org/10.1016/j.mayocp.2012.06.003 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Scialom S, Malamut G, Meresse B, Guegan N, Brousse N, Verkarre V, Derrieux C, Macintyre E, Seksik P, Savoye G, Cadiot G, Vuitton L, Marthey L, Carbonnel F, Cerf-Bensussan N, Cellier C (2015) Gastrointestinal disorder associated with olmesartan mimics autoimmune enteropathy. PLoS One 10(6):e0125024.  https://doi.org/10.1371/journal.pone.0125024 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, Mesnard B, Chayvialle JA, Savoye G, Druez A, Parlier D, Abitbol V, Gompel M, Eoche M, Poncin E, Bobichon R, Colardelle P, Wils P, Salloum H, Peschard S, Zerbib F, Meresse B, Cerf-Bensussan N, Malamut G, Carbonnel F (2014) Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther 40(9):1103–1109.  https://doi.org/10.1111/apt.12937 CrossRefPubMedGoogle Scholar
  54. 54.
    Esteve M, Temino R, Carrasco A, Batista L, Del Val A, Ble M, Santaolaria S, Molina-Infante J, Soriano G, Agudo S, Zabana Y, Andujar X, Aceituno M, Ribes J, Madridejos R, Fernandez-Banares F (2016) Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: a population-based study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 48(2):154–161.  https://doi.org/10.1016/j.dld.2015.09.014 CrossRefGoogle Scholar
  55. 55.
    Lagana SM, Braunstein ED, Arguelles-Grande C, Bhagat G, Green PH, Lebwohl B (2015) Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. J Clin Pathol 68(1):29–32.  https://doi.org/10.1136/jclinpath-2014-202615 CrossRefPubMedGoogle Scholar
  56. 56.
    Marietta EV, Nadeau AM, Cartee AK, Singh I, Rishi A, Choung RS, TT W, Rubio-Tapia A, Murray JA (2015) Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther 42(11–12):1303–1314.  https://doi.org/10.1111/apt.13413 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Gentile NM, Murray JA, Pardi DS (2012) Autoimmune enteropathy: a review and update of clinical management. Current gastroenterology reports 14(5):380–385.  https://doi.org/10.1007/s11894-012-0276-2 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Ruemmele FM, Brousse N, Goulet O (2004) Autoimmune enteropathy: molecular concepts. Curr Opin Gastroenterol 20(6):587–591CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Sarah E. Umetsu
    • 1
  • Ian Brown
    • 2
  • Cord Langner
    • 3
  • Gregory Y. Lauwers
    • 4
  1. 1.Department of PathologyUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Envoi PathologyKelvin GroveAustralia
  3. 3.Institute of PathologyMedical University of GrazGrazAustria
  4. 4.Department of PathologyMoffitt Cancer CenterTampaUSA

Personalised recommendations